Cyclerion Partners with Medsteer to Advance Depression Treatment
Cyclerion Therapeutics teams up with Medsteer to develop CYC-126, an innovative therapy for treatment-resistant depression, with Phase 2 trials starting in 2026.
/ 1662 items
#XY↓
Novo Nordisk Launches Wegovy Weight-Loss Pill in the U.S.
Novo Nordisk's once-daily Wegovy pill launches in the U.S. at $149/month for self-paying customers, intensifying competition with Eli Lilly in the weight-loss drug market.
Gyre Therapeutics Gains on China Drug Approval Pathway
Gyre Therapeutics (GYRE) stock jumps 14% after Chinese regulators agree to conditional approval pathway for Hydronidone, a first-in-class liver fibrosis treatment.
Altimmune Stock Surges on FDA Breakthrough Designation for Liver Disease Treatment
Altimmune shares jump 24% after FDA grants breakthrough therapy designation for pemvidutide, a promising treatment for MASH liver disease showing significant trial results.
Zenas BioPharma Crashes 53% Despite Meeting Trial Goals—Why Investors Aren't Buying It
Zenas BioPharma stock plunges over 50% after Phase 3 obexelimab trial results disappoint Wall Street, despite meeting all endpoints in rare autoimmune disease study.
Neumora Shows Promise with New Alzheimer's Agitation Treatment
Neumora Therapeutics (NMRA) announces positive Phase 1b results for NMRA-511, a new drug candidate showing clinically meaningful improvements in Alzheimer's disease agitation symptoms with favorable safety profile.